Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (n = 258) with malignant ascites, catumaxomab showed a clear clinical benefit vs. paracentesis and had an acceptable safety profile. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Ott, Marion G, Marmé, Frederik, Moldenhauer, Gerhard, Lindhofer, Horst, Hennig, Michael, Spannagl, Rolf, Essing, Mirko M, Linke, Rolf, Seimetz, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:
Cancer Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415680/
https://www.ncbi.nlm.nih.gov/pubmed/21702044
http://dx.doi.org/10.1002/ijc.26258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415680/
https://www.ncbi.nlm.nih.gov/pubmed/21702044
http://dx.doi.org/10.1002/ijc.26258

Ejemplares similares